title: [Follow-up of node-negative patients with breast cancer].
abstract: In 136 cases of nodal-negative breast cancer, the further course regarding the incidence of metastases or recurrence was observe over a period of up to 83 months. Parameters have been tumor size, location, grading, the number of extirpated lymphatic nodules, hormone receptor status, and menopause status. After a mean observation period of 3.5 years, distant metastases had appeared in 23 cases = 16.9%. In this collective, the recurrence rate in premenopausal patients was 17.4% in postmenopausal patients ones 16.7%. An interesting trend became apparent in correlation between relapse and conducted primary therapy: All patients with tumor stage T1 who had received chemotherapy - at least one cycle of CMF - were free of relapse partially over the complete observation period. Regarding the fact that early hematogenous dissemination is also possible without involvement of regional lymphatic nodules, at least a perioperative chemotherapy appears useful. Definite statements concerning usefulness and efficiency of this mode of therapy however are only possible after evaluation of results of controlled studies.
authors.affiliation: Geburtshilflich-Gynäkologischen Abteilung, St. Lukas Klinik Solingen.
authors.forename: K
authors.initials: K
authors.lastname: Meinen
authors.forename: E H
authors.initials: EH
authors.lastname: Weih
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D011960:Receptors, Estrogen / Q000032:analysis
chemical_list: D011960:Receptors, Estrogen
vernacular_title: Verlaufskontrollen bei nodal negativen Patientinnen mit Mammakarzinom.